Secukinumab Phase III Data Look Reassuring Ahead Of Advisory Committee Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Efficacy results look solid in pair of Phase III trials published in NEJM, but some question whether a double dose adds enough to get approval. Investigators note prevalence of Candida infections in patients on the Novartis drug.